Metabolic Rewiring of Upon Drug Treatment and Antibiotics Resistance

Overview

Journal Metabolites

Publisher MDPI

Date 2024 Jan 22

PMID 38248866

Authors

Biplab Singha

Sumit Murmu

Tripti Nair

Rahul Singh Rawat

Aditya Kumar Sharma

Vijay Soni

Affiliations

Soon will be listed here.

Abstract

Tuberculosis (TB), caused by (), remains a significant global health challenge, further compounded by the issue of antimicrobial resistance (AMR). AMR is a result of several system-level molecular rearrangements enabling bacteria to evolve with better survival capacities: metabolic rewiring is one of them. In this review, we present a detailed analysis of the metabolic rewiring of in response to anti-TB drugs and elucidate the dynamic mechanisms of bacterial metabolism contributing to drug efficacy and resistance. We have discussed the current state of AMR, its role in the prevalence of the disease, and the limitations of current anti-TB drug regimens. Further, the concept of metabolic rewiring is defined, underscoring its relevance in understanding drug resistance and the biotransformation of drugs by . The review proceeds to discuss the metabolic adaptations of to drug treatment, and the pleiotropic effects of anti-TB drugs on metabolism. Next, the association between metabolic changes and antimycobacterial resistance, including intrinsic and acquired drug resistance, is discussed. The review concludes by summarizing the challenges of anti-TB treatment from a metabolic viewpoint, justifying the need for this discussion in the context of novel drug discovery, repositioning, and repurposing to control AMR in TB.

Citing Articles

Ajoene: a natural compound with enhanced antimycobacterial and antibiofilm properties mediated by efflux pump modulation and ROS generation against M. Smegmatis.

Sarangi A, Das B, Pahuja I, Ojha S, Singh V, Giri S Arch Microbiol. 2024; 206(12):453.

PMID: 39487375 DOI: 10.1007/s00203-024-04189-9.

References

Boyer E, Dessolin J, Lustig M, Decossas M, Phan G, Cece Q . Molecular Determinants for OMF Selectivity in Tripartite RND Multidrug Efflux Systems. Antibiotics (Basel). 2022; 11(2). PMC: 8868134. DOI: 10.3390/antibiotics11020126. View

McNeil M, Chettiar S, Awasthi D, Parish T . Cell wall inhibitors increase the accumulation of rifampicin in . Access Microbiol. 2020; 1(1):e000006. PMC: 7470358. DOI: 10.1099/acmi.0.000006. View

Zimmerman M, Lestner J, Prideaux B, OBrien P, Dias-Freedman I, Chen C . Ethambutol Partitioning in Tuberculous Pulmonary Lesions Explains Its Clinical Efficacy. Antimicrob Agents Chemother. 2017; 61(9). PMC: 5571334. DOI: 10.1128/AAC.00924-17. View

Lupien A, Vocat A, Foo C, Blattes E, Gillon J, Makarov V . Optimized Background Regimen for Treatment of Active Tuberculosis with the Next-Generation Benzothiazinone Macozinone (PBTZ169). Antimicrob Agents Chemother. 2018; 62(11). PMC: 6201121. DOI: 10.1128/AAC.00840-18. View

Wang F, Cassidy C, Sacchettini J . Crystal structure and activity studies of the Mycobacterium tuberculosis beta-lactamase reveal its critical role in resistance to beta-lactam antibiotics. Antimicrob Agents Chemother. 2006; 50(8):2762-71. PMC: 1538687. DOI: 10.1128/AAC.00320-06. View

Lee J, Lee S, Song N, Nathan T, Swarts B, Eum S . Transient drug-tolerance and permanent drug-resistance rely on the trehalose-catalytic shift in Mycobacterium tuberculosis. Nat Commun. 2019; 10(1):2928. PMC: 6606615. DOI: 10.1038/s41467-019-10975-7. View

Moreland , Goldstein I , Kim , Traish . Sildenafil Citrate, a Selective Phosphodiesterase Type 5 Inhibitor:. Trends Endocrinol Metab. 1999; 10(3):97-104. DOI: 10.1016/s1043-2760(98)00127-1. View

Malik S, Willby M, Sikes D, Tsodikov O, Posey J . New insights into fluoroquinolone resistance in Mycobacterium tuberculosis: functional genetic analysis of gyrA and gyrB mutations. PLoS One. 2012; 7(6):e39754. PMC: 3386181. DOI: 10.1371/journal.pone.0039754. View

Mori G, Orena B, Franch C, Mitchenall L, Godbole A, Rodrigues L . The EU approved antimalarial pyronaridine shows antitubercular activity and synergy with rifampicin, targeting RNA polymerase. Tuberculosis (Edinb). 2018; 112:98-109. DOI: 10.1016/j.tube.2018.08.004. View

10.

Safi H, Gopal P, Lingaraju S, Ma S, Levine C, Dartois V . Phase variation in produces transiently heritable drug tolerance. Proc Natl Acad Sci U S A. 2019; 116(39):19665-19674. PMC: 6765255. DOI: 10.1073/pnas.1907631116. View

11.

Gygli S, Borrell S, Trauner A, Gagneux S . Antimicrobial resistance in Mycobacterium tuberculosis: mechanistic and evolutionary perspectives. FEMS Microbiol Rev. 2017; 41(3):354-373. DOI: 10.1093/femsre/fux011. View

12.

Evans J, Trujillo C, Wang Z, Eoh H, Ehrt S, Schnappinger D . Validation of CoaBC as a Bactericidal Target in the Coenzyme A Pathway of Mycobacterium tuberculosis. ACS Infect Dis. 2016; 2(12):958-968. PMC: 5153693. DOI: 10.1021/acsinfecdis.6b00150. View

13.

Wilson M, Derisi J, Kristensen H, Imboden P, Rane S, Brown P . Exploring drug-induced alterations in gene expression in Mycobacterium tuberculosis by microarray hybridization. Proc Natl Acad Sci U S A. 1999; 96(22):12833-8. PMC: 23119. DOI: 10.1073/pnas.96.22.12833. View

14.

Galietti F, Giorgis G, Oliaro A, Boaro D, Ardizzi A, Barberis S . [Tolerability to terizidone (TZ) in the treatment of pulmonary tuberculosis in dialyzed patients]. Minerva Med. 1991; 82(7-8):477-81. View

15.

Sarathy J, Via L, Weiner D, Blanc L, Boshoff H, Eugenin E . Extreme Drug Tolerance of Mycobacterium tuberculosis in Caseum. Antimicrob Agents Chemother. 2017; 62(2). PMC: 5786764. DOI: 10.1128/AAC.02266-17. View

16.

Puckett S, Trujillo C, Wang Z, Eoh H, Ioerger T, Krieger I . Glyoxylate detoxification is an essential function of malate synthase required for carbon assimilation in . Proc Natl Acad Sci U S A. 2017; 114(11):E2225-E2232. PMC: 5358392. DOI: 10.1073/pnas.1617655114. View

17.

Bellerose M, Baek S, Huang C, Moss C, Koh E, Proulx M . Common Variants in the Glycerol Kinase Gene Reduce Tuberculosis Drug Efficacy. mBio. 2019; 10(4). PMC: 6667613. DOI: 10.1128/mBio.00663-19. View

18.

Adams K, Takaki K, Connolly L, Wiedenhoft H, Winglee K, Humbert O . Drug tolerance in replicating mycobacteria mediated by a macrophage-induced efflux mechanism. Cell. 2011; 145(1):39-53. PMC: 3117281. DOI: 10.1016/j.cell.2011.02.022. View

19.

Miller D . Review of moxifloxacin hydrochloride ophthalmic solution in the treatment of bacterial eye infections. Clin Ophthalmol. 2009; 2(1):77-91. PMC: 2698721. DOI: 10.2147/opth.s1666. View

20.

Quemard A, LANEELLE G, LACAVE C . Mycolic acid synthesis: a target for ethionamide in mycobacteria?. Antimicrob Agents Chemother. 1992; 36(6):1316-21. PMC: 190338. DOI: 10.1128/AAC.36.6.1316. View